Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is the most lethal malignancy of prostate cancer (PCa). Treatment with next-generation androgen receptor (AR) pathway inhibitors (ARPIs) has successfully extended patients' lifespan. However, with the emergence of drug resistance, PCa tumors increasingly ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wen-Chi, Wang, Hung-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323647/
https://www.ncbi.nlm.nih.gov/pubmed/34386358
http://dx.doi.org/10.4103/tcmj.tcmj_220_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323647/
https://www.ncbi.nlm.nih.gov/pubmed/34386358
http://dx.doi.org/10.4103/tcmj.tcmj_220_20

Ejemplares similares